{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:23:41Z","timestamp":1791822221845,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,9]]},"DOI":"10.7759\/cureus.57894","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T11:19:05Z","timestamp":1712661545000},"source":"Crossref","is-referenced-by-count":5,"title":["The Development of Diabetes and Diabetic Ketoacidosis Following Immunotherapy Treatment: A Systematic Review of Case Reports"],"prefix":"10.7759","author":[{"given":"Stephanie","family":"Nagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Demory Beckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc M","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang C","year":"2022","unstructured":"Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022, 12:2115-32. 10.7150\/thno.69424","journal-title":"Theranostics"},{"key":"ref2","unstructured":"The global cancer observatory. (2022). Accessed. Dec 4, 2023: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/39-All-cancers-fact-sheet.pdf."},{"key":"ref3","article-title":"Cancer chemotherapy","author":"Amjad M","unstructured":"Amjad M, Chidharla A, Kasi A. Cancer chemotherapy. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564367\/:"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i9.712","article-title":"Embracing cancer immunotherapy with vital micronutrients","volume":"12","author":"Yuen RC","year":"2021","unstructured":"Yuen RC, Tsao SY. Embracing cancer immunotherapy with vital micronutrients. World J Clin Oncol. 2021, 12:712-24. 10.5306\/wjco.v12.i9.712","journal-title":"World J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.820302","article-title":"Comparison of immunotherapy, chemotherapy, and chemoimmunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma: a retrospective study","volume":"12","author":"Xiao Y","year":"2022","unstructured":"Xiao Y, He J, Luo S, et al.. Comparison of immunotherapy, chemotherapy, and chemoimmunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma: a retrospective study. Front Oncol. 2022, 12:820302. 10.3389\/fonc.2022.820302","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi D","year":"2020","unstructured":"Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel). 2020, 9:34. 10.3390\/antib9030034","journal-title":"Antibodies (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder E","year":"2016","unstructured":"Buchbinder E, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016, 39:98-106. 10.1097\/COC.0000000000000239","journal-title":"Am J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins S","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019, 94:S3-9. 10.1002\/ajh.25418","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03437-0","article-title":"Natural killer cells: a promising immunotherapy for cancer","volume":"20","author":"Chu J","year":"2022","unstructured":"Chu J, Gao F, Yan M, Zhao S, Yan Z, Shi B, Liu Y. Natural killer cells: a promising immunotherapy for cancer. J Transl Med. 2022, 20:240. 10.1186\/s12967-022-03437-0","journal-title":"J Transl Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.5009","article-title":"Immunotherapy adverse effects","volume":"7","author":"Brown TJ","year":"2021","unstructured":"Brown TJ, Mamtani R, Bange EM. Immunotherapy adverse effects. JAMA Oncol. 2021, 7:1908. 10.1001\/jamaoncol.2021.5009","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol M","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ, et al.. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017, 58:70-6. 10.1016\/j.ctrv.2017.06.002","journal-title":"Cancer Treat Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.606434","article-title":"New insights into the role of autoreactive CD8 T cells and cytokines in human type 1 diabetes","volume":"11","author":"Bender C","year":"2020","unstructured":"Bender C, Rajendran S, von Herrath MG. New insights into the role of autoreactive CD8 T cells and cytokines in human type 1 diabetes. Front Endocrinol (Lausanne). 2020, 11:606434. 10.3389\/fendo.2020.606434","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref13","article-title":"Chapter 7: systematic reviews of etiology and risk","author":"Moola S","year":"2020","unstructured":"Moola S, Munn Z, Tufanaru C, et.. Chapter 7: systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis. Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z (ed): JBI, 2020."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/03000605221121940","article-title":"Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases","volume":"50","author":"Luo J","year":"2022","unstructured":"Luo J, Feng J, Liu C, et al.. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases. J Int Med Res. 2022, 50:3000605221121940. 10.1177\/03000605221121940","journal-title":"J Int Med Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0480-y","article-title":"Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature","volume":"12","author":"Hickmott L","year":"2017","unstructured":"Hickmott L, De La Pe\u00f1a H, Turner H, Ahmed F, Protheroe A, Grossman A, Gupta A. Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature. Target Oncol. 2017, 12:235-41. 10.1007\/s11523-017-0480-y","journal-title":"Target Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4151","article-title":"Diabetes mellitus secondary to treatment with immune checkpoint inhibitors","volume":"26","author":"Venetsanaki V","year":"2019","unstructured":"Venetsanaki V, Boutis A, Chrisoulidou A, Papakotoulas P. Diabetes mellitus secondary to treatment with immune checkpoint inhibitors. Curr Oncol. 2019, 26:111-4. 10.3747\/co.26.4151","journal-title":"Curr Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jppr.1436","article-title":"Pembrolizumab: a case of drug-induced autoimmune diabetes mellitus and colitis","volume":"49","author":"Singh N","year":"2018","unstructured":"Singh N. Pembrolizumab: a case of drug-induced autoimmune diabetes mellitus and colitis. J Pharm Pract. 2018, 49:50-4. 10.1002\/jppr.1436","journal-title":"J Pharm Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jppr.1329","article-title":"Pembrolizumab-induced auto-immune type-1 diabetes in a patient with metastatic melanoma","volume":"48","author":"Reslan Z","year":"2018","unstructured":"Reslan Z, Bennett M, Wong E, Jacques S, Lee A. Pembrolizumab-induced auto-immune type-1 diabetes in a patient with metastatic melanoma. J Pharm Pract. 2018, 48:262-4. 10.1002\/jppr.1329","journal-title":"J Pharm Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1913-7","article-title":"A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes","volume":"66","author":"Chae YK","year":"2017","unstructured":"Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother. 2017, 66:25-32. 10.1007\/s00262-016-1913-7","journal-title":"Cancer Immunol Immunother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1835-4","article-title":"A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome","volume":"65","author":"Hansen E","year":"2016","unstructured":"Hansen E, Sahasrabudhe D, Sievert L. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. 2016, 65:765-7. 10.1007\/s00262-016-1835-4","journal-title":"Cancer Immunol Immunother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review","volume":"66","author":"Gauci ML","year":"2017","unstructured":"Gauci ML, Laly P, Vidal-Trecan T, et al.. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother. 2017, 66:1399-410. 10.1007\/s00262-017-2033-8","journal-title":"Cancer Immunol Immunother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10632","article-title":"Diabetic ketoacidosis: an adverse reaction to immunotherapy","volume":"12","author":"Keerty D","year":"2020","unstructured":"Keerty D, Das M, Hallanger-Johnson J, Haynes E. Diabetic ketoacidosis: an adverse reaction to immunotherapy. Cureus. 2020, 12:e10632. 10.7759\/cureus.10632","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.931702","article-title":"A severe case of diabetic ketoacidosis and new-onset type 1 diabetes mellitus associated with anti-glutamic acid decarboxylase antibodies following immunotherapy with pembrolizumab","volume":"22","author":"Kedzior SK","year":"2021","unstructured":"Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH. A severe case of diabetic ketoacidosis and new-onset type 1 diabetes mellitus associated with anti-glutamic acid decarboxylase antibodies following immunotherapy with pembrolizumab. Am J Case Rep. 2021, 22:e931702. 10.12659\/AJCR.931702","journal-title":"Am J Case Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2020.09.023","article-title":"Diabetic ketoacidosis as a delayed immune-related event after discontinuation of nivolumab","volume":"60","author":"Mae S","year":"2021","unstructured":"Mae S, Kuriyama A, Tachibana H. Diabetic ketoacidosis as a delayed immune-related event after discontinuation of nivolumab. J Emerg Med. 2021, 60:342-4. 10.1016\/j.jemermed.2020.09.023","journal-title":"J Emerg Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/2324709620951339","article-title":"Pembrolizumab-induced diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic colonic adenocarcinoma","volume":"8","author":"Kichloo A","year":"2020","unstructured":"Kichloo A, Albosta M, McMahon S, et al.. Pembrolizumab-induced diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic colonic adenocarcinoma. J Investig Med High Impact Case Rep. 2020, 8:2324709620951339. 10.1177\/2324709620951339","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000173","article-title":"Diabetic ketoacidosis as an immune-related adverse event from Pembrolizumab in non-small cell lung cancer","volume":"40","author":"Leonardi GC","year":"2017","unstructured":"Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM. Diabetic ketoacidosis as an immune-related adverse event from Pembrolizumab in non-small cell lung cancer. J Immunother. 2017, 40:249-51. 10.1097\/CJI.0000000000000173","journal-title":"J Immunother"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0303-9","article-title":"Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma","volume":"5","author":"Changizzadeh PN","year":"2017","unstructured":"Changizzadeh PN, Mukkamalla SK, Armenio VA. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma. J Immunother Cancer. 2017, 5:1-4. 10.1186\/s40425-017-0303-9","journal-title":"J Immunother Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0245-2","article-title":"Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer","volume":"5","author":"Godwin JL","year":"2017","unstructured":"Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer. 2017, 5:1-7. 10.1186\/s40425-017-0245-2","journal-title":"J Immunother Cancer"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02502-w","article-title":"Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report","volume":"14","author":"Porntharukchareon T","year":"2020","unstructured":"Porntharukchareon T, Tontivuthikul B, Sintawichai N, Srichomkwun P. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report. J Med Case Rep. 2020, 14:171. 10.1186\/s13256-020-02502-w","journal-title":"J Med Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.15277\/bjd.2023.410","article-title":"Pembrolizumab and diabetes: a case of diabetic ketoacidosis in a patient with metastatic melanoma","volume":"23","author":"Lolomari S","year":"2023","unstructured":"Lolomari S, Thayyil S, Kong M. Pembrolizumab and diabetes: a case of diabetic ketoacidosis in a patient with metastatic melanoma.  Br J Diabetes. 2023, 23:45-7. 10.15277\/bjd.2023.410","journal-title":"Br J Diabetes"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35276","article-title":"A case of pembrolizumab-induced diabetic ketoacidosis and hyperthyroidism in a patient with recurrent esophageal adenocarcinoma","volume":"15","author":"Salangsang J","year":"2023","unstructured":"Salangsang J, Sapkota S, Kharel S, Gupta P, Kalla A. A case of pembrolizumab-induced diabetic ketoacidosis and hyperthyroidism in a patient with recurrent esophageal adenocarcinoma. Cureus. 2023, 15:e35276. 10.7759\/cureus.35276","journal-title":"Cureus"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-18-0111","article-title":"Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis","volume":"2018","author":"Tzoulis P","year":"2018","unstructured":"Tzoulis P, Corbett RW, Ponnampalam S, Baker E, Heaton D, Doulgeraki T, Stebbing J. Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis. Endocrinol Diabetes Metab Case Rep. 2018, 2018:10.1530\/EDM-18-0111","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.239.155","article-title":"Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes","volume":"239","author":"Miyoshi Y","year":"2016","unstructured":"Miyoshi Y, Ogawa O, Oyama Y. Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes. Tohoku J Exp Med. 2016, 239:155-8. 10.1620\/tjem.239.155","journal-title":"Tohoku J Exp Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24479","article-title":"New-onset autoimmune diabetes mellitus presenting as diabetic ketoacidosis in association with pembrolizumab therapy and long term follow-up: case report","volume":"14","author":"Pachpande V","year":"2022","unstructured":"Pachpande V, Mullangi S, Lekkala MR, Patel A. New-onset autoimmune diabetes mellitus presenting as diabetic ketoacidosis in association with pembrolizumab therapy and long term follow-up: case report. Cureus. 2022, 14:e24479. 10.7759\/cureus.24479","journal-title":"Cureus"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-22-0387","article-title":"Toripalimab-associated diabetes mellitus: a case report from the community of Southern China","volume":"2","author":"Zhang W","year":"2023","unstructured":"Zhang W, Xu W. Toripalimab-associated diabetes mellitus: a case report from the community of Southern China. Endocrinol Diabetes Metab Case Rep. 2023, 2:10.1530\/EDM-22-0387","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00352","article-title":"Atezolizumab-induced autoimmune diabetes in a patient with metastatic lung cancer","volume":"10","author":"Sothornwit J","year":"2019","unstructured":"Sothornwit J, Phunmanee A, Pongchaiyakul C. Atezolizumab-induced autoimmune diabetes in a patient with metastatic lung cancer. Front Endocrinol (Lausanne). 2019, 10:352. 10.3389\/fendo.2019.00352","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001163","article-title":"Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report","volume":"33","author":"Fu L","year":"2022","unstructured":"Fu L, Chen P, Wang S, Liu W, Chen Z, Chen H, Fu Z. Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report. Anticancer Drugs. 2022, 33:e741-6. 10.1097\/CAD.0000000000001163","journal-title":"Anticancer Drugs"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02076","article-title":"Sintilimab-induced autoimmune diabetes in a patient with the anti-tumor effect of partial regression","volume":"11","author":"Wen L","year":"2020","unstructured":"Wen L, Zou X, Chen Y, Bai X, Liang T. Sintilimab-induced autoimmune diabetes in a patient with the anti-tumor effect of partial regression. Front Immunol. 2020, 11:2076. 10.3389\/fimmu.2020.02076","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-21-0123","article-title":"New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer","volume":"1","author":"Cunha C","year":"2022","unstructured":"Cunha C, Silva E, Vieira AC, Saraiva C, Duarte S. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer. Endocrinol Diabetes Metab Case Rep. 2022, 1:121-3. 10.1530\/EDM-21-0123","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14736","article-title":"Late-onset acute type 1 diabetes mellitus 7\u2009months after discontinuation of pembrolizumab against lung cancer","volume":"14","author":"Ichihara S","year":"2023","unstructured":"Ichihara S, Kunishige M, Kadota N, et al.. Late-onset acute type 1 diabetes mellitus 7\u2009months after discontinuation of pembrolizumab against lung cancer. Thorac Cancer. 2023, 14:81-4. 10.1111\/1759-7714.14736","journal-title":"Thorac Cancer"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8981375","article-title":"Fulminant diabetes in a patient with advanced melanoma on nivolumab","volume":"2018","author":"Chokr N","year":"2018","unstructured":"Chokr N, Farooq H, Guadalupe E. Fulminant diabetes in a patient with advanced melanoma on nivolumab. Case Rep Oncol Med. 2018, 2018:8981375. 10.1155\/2018\/8981375","journal-title":"Case Rep Oncol Med"},{"key":"ref42","unstructured":"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults. (2023). Accessed. Dec 11, 2023: https:\/\/www.uptodate.com\/contents\/clinical-presentation-diagnosis-and-initial-evaluation-of-diabetes-mellitus-in-adults."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen MC","year":"2018","unstructured":"Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018, 98:2133-223. 10.1152\/physrev.00063.2017","journal-title":"Physiol Rev"},{"key":"ref44","unstructured":"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults. clinical features, evaluation, and diagnosis. (2022). Accessed: Dec 12, 2023: https:\/\/medilib.ir\/uptodate\/show\/1792."},{"key":"ref45","article-title":"Hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state","author":"Gosmanova A","year":"2000","unstructured":"Gosmanova A, Gosmanova E, Kitabchi E. Hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endotext [Internet]. Feingold KR, Anawalt B, Blackman MR, et al. (ed): MDText.com, Inc., South Dartmouth (MA); 2000."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1713543114","article-title":"Resident macrophages of pancreatic islets have a seminal role in the initiation of autoimmune diabetes of NOD mice","volume":"114","author":"Carrero JA","year":"2017","unstructured":"Carrero JA, McCarthy DP, Ferris ST, et al.. Resident macrophages of pancreatic islets have a seminal role in the initiation of autoimmune diabetes of NOD mice. Proc Natl Acad Sci USA. 2017, 114:E10418-27. 10.1073\/pnas.1713543114","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal A","year":"2019","unstructured":"Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019, 7:e000591. 10.1136\/bmjdrc-2018-000591","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2015.0417","article-title":"Continuous glucose monitoring: a review of successes, challenges, and opportunities","volume":"18","author":"Rodbard D","year":"2016","unstructured":"Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016, 18:S3-S13. 10.1089\/dia.2015.0417","journal-title":"Diabetes Technol Ther"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1690","article-title":"Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the relief study","volume":"44","author":"Roussel R","year":"2021","unstructured":"Roussel R, Riveline JP, Vicaut E, et al.. Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the relief study. Diabetes Care. 2021, 44:1368-76. 10.2337\/dc20-1690","journal-title":"Diabetes Care"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306691","article-title":"Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes","volume":"389","author":"Waibel M","year":"2023","unstructured":"Waibel M, Wentworth JM, So M, et al.. Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes. N Engl J Med. 2023, 389:2140-50. 10.1056\/NEJMoa2306691","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/235363-the-development-of-diabetes-and-diabetic-ketoacidosis-following-immunotherapy-treatment-a-systematic-review-of-case-reports","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T11:19:10Z","timestamp":1712661550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/235363-the-development-of-diabetes-and-diabetic-ketoacidosis-following-immunotherapy-treatment-a-systematic-review-of-case-reports"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.57894","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}